BTK Inhibitors for the Treatment of CLL: Are they all the same?

In this episode, we discuss the use of Bruton’s Tyrosine Kinase (BTK) inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL). 

Included is a discussion of:

• Novel treatments for CLL
• The impact of BTK inhibitors for the treatment of CLL
• The differences between first- (e.g. ibrutinib) and second-generation (e.g. acalabrutinib, zanubrutinib, tirabrutinib) BTK inhibitors
• Preliminary results from the ELEVATE-RR trial comparing the efficacy and safety of acalabrutinib vs ibrutinib in high-risk relapsed/refractory CLL (see: https://www.cancernetwork.com/view/acalabrutinib-meets-primary-end-point-versus-ibrutinib-in-previously-treated-high-risk-cll for the full press release)

Our guest:
Dr. Carolyn Owen is an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her internal medicine training in Ottawa, followed by Hematology training in Vancouver and a research fellowship in molecular genetics at Barts and the London School of Medicine. Her current clinical interests are in the areas of low-grade lymphoma and chronic lymphocytic leukemia (or CLL) and she is the local principal investigator at the Tom Baker Cancer Centre for a number of clinical trials focusing on these areas.

Funding for this episode provided by AstraZeneca, Canada. If you in enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.